Research Paper Volume 11, Issue 9 pp 2724—2734

Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients

Figure 1. Flowchart for the procedures in selecting a propensity score matched cohort of rosiglitazone ever users and never users.